Helomics™ CEO Named to Pennsylvania Bio Board of Directors

PITTSBURGH--()--Helomics Corporation, a privately-held personalized healthcare company that provides comprehensive tumor profiling products and services based on both live and fixed cell assays, announced today that the Company’s President, CEO and Founder, Neil Campbell, was elected to join the Pennsylvania Bio Board of Directors.

“Pennsylvania has a strong life sciences industry that has cultivated a supportive and encouraging environment for Helomics to grow as a company. I look forward to collaborating with this esteemed group of industry leaders to foster the growth and success of life sciences in our state.”

Pennsylvania Bio is a statewide trade association representing the commonwealth’s life sciences industry. The association was founded 25 years ago by a group of Biotech CEOs. Today it’s grown to represent the entire life sciences industry – medical device and diagnostics companies, pharmaceutical companies, investment organizations, academic institutions, and myriad service industries that support the life sciences in Pennsylvania.

“It is an honor to join the Pennsylvania Bio Board of Directors,” said Neil Campbell. “Pennsylvania has a strong life sciences industry that has cultivated a supportive and encouraging environment for Helomics to grow as a company. I look forward to collaborating with this esteemed group of industry leaders to foster the growth and success of life sciences in our state.”

About Pennsylvania Bio

Pennsylvania Bio is the statewide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is a global leader in the life sciences by developing a business and public policy environment, which fosters life science growth and success. More information is available at http://www.pabio.org.

About Helomics Corporation, Inc.

Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com